Skip to content

Buprenorphine

Partial Opioid Agonist — NERVOUS SYSTEM

Also known as: buprenorfine, buprenorphine HCl, buprenorphine hydrochloride, norspan

OfpEMA approvedFDA approvedATC N02AE01ATC N07BC01ATC N07BC51

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Buprenorphine is an ofp drug in the Partial Opioid Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1981. Its mechanism of action is classified as Partial Opioid Agonists. DrugCentral lists 9 molecular targets, including Oprm1, OPRM1 and Oprd1. Recorded indications include Acute postoperative pain, Chronic pain, Chronic Pain with Opioid Tolerance and Opioid dependence.

  • Approval status: ofp (first approved 1981 by the FDA).
  • Drug class: Partial Opioid Agonist.
  • Mechanism of action: Partial Opioid Agonists.
  • Molecular targets: Oprm1, OPRM1, Oprd1 and OPRK1 (9 listed in DrugCentral).
  • Indications: Acute postoperative pain, Chronic pain, Chronic Pain with Opioid Tolerance, Opioid dependence and Prevention of opioid abuse and others.
  • ATC code: N02AE01 (Oripavine derivatives).
  • Molecular formula: C29H41NO4; molecular weight 467.65 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

  • Acute postoperative pain
  • Chronic pain
  • Chronic Pain with Opioid Tolerance
  • Opioid dependence
  • Prevention of opioid abuse
  • Severe pain

Off-label uses (1)

  • Opioid withdrawal

Contraindications (32)

  • Adrenal cortical hypofunction
  • Alcohol intoxication
  • Alcohol withdrawal delirium
  • Asthenia
  • Benign intracranial hypertension
  • Benign prostatic hyperplasia
  • Central nervous system depression
  • Chronic disease of respiratory system
  • Chronic hepatitis C
  • Chronic obstructive lung disease
  • Chronic type B viral hepatitis
  • Congenital long QT syndrome
  • Cor pulmonale
  • Decreased respiratory function
  • Dependent drug abuse
  • Disease of liver
  • Disorder of biliary tract
  • Drug-induced psychosis
  • Hypercapnia
  • Hypothyroidism
  • Hypoxia
  • Injury of head
  • Kyphoscoliosis with Respiratory Compromise
  • Lesion of brain
  • Liver function tests abnormal
  • Orthostatic hypotension
  • Pain in Opioid Naive Patients
  • Paralytic ileus
  • Prolonged QT interval
  • Respiratory insufficiency
  • + 2 more

Mechanism & targets

Mechanism of action (MoA)Partial Opioid Agonists
Established pharmacologic classPartial Opioid Agonist

Molecular targets (9)

TargetGeneActionActivity
Mu-type opioid receptorOprm1unknownKi 9.89
Mu-type opioid receptorOPRM1unknownKi 9.40
Delta-type opioid receptorOprd1unknownKi 9.32
Kappa-type opioid receptorOPRK1unknownKi 9.30
Kappa-type opioid receptorOPRK1antagonistKi 9.01
Mu-type opioid receptorOPRM1partial agonistKi 8.29
Delta-type opioid receptorOPRD1antagonistKi 8.07
Nociceptin receptorOPRL1unknownKi 7.11
Potassium voltage-gated channel subfamily H member 2KCNH2unknownIC50 5.10

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2019-06-19EMA—L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.
1981-12-29FDA—RECKITT BENCKISER

ATC classification

ATC codeTherapeutic hierarchy
N02AE01NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Oripavine derivatives
N07BC01NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › DRUGS USED IN ADDICTIVE DISORDERS › Drugs used in opioid dependence
N07BC51NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › DRUGS USED IN ADDICTIVE DISORDERS › Drugs used in opioid dependence

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Drug withdrawal syndrome4075.0
Drug abuse3550.4
Product adhesion issue1993.2
Drug dependence1761.6
Application site pruritus1758.5
Drug withdrawal syndrome neonatal1757.9
Application site erythema1232.7
Substance abuse1156.7
Application site rash1027.9
Drug use disorder1020.1
Withdrawal syndrome1002.0
Blepharospasm937.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Buprenorphine is on its molecule page.

Molecular formulaC29H41NO4
Molecular weight467.65 g/mol
CAS number52485-79-7
InChIKeyRMRJXGBAOAMLHD-IHFGGWKQSA-N
PubChem CID644073
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Buprenorphine used for?

DrugCentral lists the following indications for Buprenorphine: Acute postoperative pain, Chronic pain, Chronic Pain with Opioid Tolerance, Opioid dependence, Prevention of opioid abuse and Severe pain.

How does Buprenorphine work?

Buprenorphine is classified as Partial Opioid Agonists; its molecular targets in DrugCentral include Oprm1, OPRM1, Oprd1 and OPRK1.

When was Buprenorphine first approved?

Buprenorphine was first approved by the FDA in 1981.

What drug class does Buprenorphine belong to?

Buprenorphine is in the Partial Opioid Agonist class.

What is the chemical formula of Buprenorphine?

Buprenorphine has the molecular formula C29H41NO4 and a molecular weight of 467.65 g/mol.

Browse: all drugs starting with B · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1981-12-29
AgencyFDA
Targets9
Indications6
FormulaC29H41NO4
DrugCentral ID434
Interactive profile